Outlook Therapeutics, Inc.
Clinical trials sponsored by Outlook Therapeutics, Inc., explained in plain language.
Biopharmaceutical company developing ophthalmic therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Can a new eye injection save vision in wet AMD?
Disease control CompletedThis clinical trial is testing whether an experimental eye injection called ONS-5010 (bevacizumab) can help preserve vision in people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The study will compare ONS-5010 to an existing treatment, ranibiz…
Phase 3 • Sponsor: Outlook Therapeutics, Inc. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New eye drug aims to save sight in wet AMD
Disease control CompletedThis trial tests whether an experimental drug called ONS-5010 (a form of bevacizumab) works as well as an approved drug, Lucentis, for treating wet age-related macular degeneration (AMD). Wet AMD causes rapid vision loss due to abnormal blood vessels leaking fluid in the eye. Abo…
Phase 3 • Sponsor: Outlook Therapeutics, Inc. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Eye injection aims to tame leading causes of blindness
Disease control CompletedThis study tests the safety of an experimental eye injection called ONS-5010 (bevacizumab) in people with vision loss from wet age-related macular degeneration, diabetic macular edema, or branch retinal vein occlusion. Participants receive the injection and are monitored for side…
Phase 3 • Sponsor: Outlook Therapeutics, Inc. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC